Could a single pill prevent HIV and STIs? new study tests doxycycline doses
NCT ID NCT05853120
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 35 times
Summary
This study looked at how different doses of the antibiotic doxycycline reach tissues in the body, with the goal of creating a single-dose pill that could protect against both HIV and other sexually transmitted infections. Researchers enrolled 45 healthy adults and measured drug levels in rectal and vaginal tissues after one dose and after five doses. The results will help design future prevention strategies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEXUALLY TRANSMITTED DISEASES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hope Clinic
Atlanta, Georgia, 30322, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
doxycycline
What this could lead to
If successful, this could help create a single-dose pill that protects against both HIV and other sexually transmitted infections.
What could go wrong
This is a small, early-phase study focused on drug levels in tissues, not on actual infection prevention. The results may not lead to an effective prevention strategy.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.